On June 26, 2015 Cantargia reported that it has acquired a non-exclusive license to the POTELLIGENT Technology platform for the production of the proprietary product candidate CAN04 (Press release, Kyowa Hakko Kirin, JUN 26, 2015, View Source [SID:1234505807]). The POTELLIGENT Technology platform has been designed for research and development of antibody dependent cellular cytotoxicity (ADCC) enhanced antibodies. Commercial details of the agreement were not disclosed. Schedule your 30 min Free 1stOncology Demo! The POTELLIGENT Technology platform will be used to produce Cantargia’s lead product candidate, the monoclonal antibody CAN04 directed against the target molecule IL1RAP. The molecule IL1RAP is expressed on both cancer stem cells and mature cancer cells. CAN04 has a mode of action combining the blocking of IL-1 signaling in the cancer cell and ADCC. By using the POTELLIGENT Technology platform, a significantly enhanced ADCC activity can be obtained leading to increased efficacy.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"By utilizing BioWa’s POTELLIGENT Technology, CAN04 can be produced with significantly higher potency than normally obtained in a standard production system", says Göran Forsberg, CEO of Cantargia. "This will be a very important tool to augment the antitumor activity of CAN04 that enables state-of-the-art production technology".
"We are extremely pleased that the value of our POTELLIGENT Technology continues to be recognized by innovative companies such as Cantargia for their antibody programs in oncology," said Yasunori Yamaguchi, President and CEO of BioWa." We are very excited to work together with Cantargia on their promising antibody program".